Last edition
News about Clinical Trials
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners have collaborated to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialise Takeda's norovirus vaccine candidate
Clinical Trials | 03/08/2021 | By Darshana | 258
Final results from the head-to-head ELEVATE-RR phase III trial of AstraZeneca's Calquence (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia
Clinical Trials | 08/06/2021 | By Darshana | 384
Novartis announced results from the pivotal phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001). The study evaluated tislelizumab in patients with unresectable recurrent locally advanced
Clinical Trials | 07/06/2021 | By Darshana | 304
CSIR and Laxai Life Sciences initiate clinical trials of drug niclosamide for Covid-19 treatment
CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated phase-II clinical trial with anti-helminitic drug niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of niclosamide for the treatment of hospitalized Covid-19 patients.
Clinical Trials | 07/06/2021 | By Darshana | 394
MSN Labs initiates phase III trial of molnupiravir to treat Covid-19 in India
MSN Laboratories, a leading integrated pharmaceutical company, has announced that it is now initiating phase III clinical trial of molnupiravir capsules for the treatment of Covid-19 in India
Clinical Trials | 25/05/2021 | By Darshana | 233
Merck announced V114, the company's investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 phase 3 pediatric clinical program. These data support the potential use of V114 in healthy infants who may have previously started a pneumococcal vaccination series
Clinical Trials | 22/05/2021 | By Darshana | 175
Transcenta Holding Limited, a global biotherapeutics company announced that the updated phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been presented as an abstract online publication
Clinical Trials | 21/05/2021 | By Darshana | 181
Biogen Inc. announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP)
Clinical Trials | 17/05/2021 | By Darshana | 577
ReGenTree LLC, a US joint venture company between GtreeBNT and RegeneRx announced results of additional analysis of the phase 3 clinical trial ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye
Clinical Trials | 15/05/2021 | By Darshana | 288
Sun Pharma Advanced Research Company Ltd. (SPARC) reported positive top-line results from its phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of open angle glaucoma or ocular hypertension
Clinical Trials | 14/05/2021 | By Darshana | 228
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy